Literature DB >> 16855463

Pharmacotherapy and postdischarge outcomes of child inpatients admitted for aggressive behavior.

Joseph C Blader1.   

Abstract

OBJECTIVES: : (1) To ascertain the use rates of specific pharmacotherapy strategies for child psychiatric inpatients with aggressive behavior from preadmission care through 12 months after discharge, and (2) To examine the associations between these strategies and postdischarge outcomes.
METHOD: : Prospective follow-up of eighty-three 5- to 13-year-old children admitted to acute inpatient care for aggressive behavior in the context of a disruptive behavior disorder. Treatment and symptom severity data were obtained at admission, discharge, and 3, 6, and 12 months after discharge between 1998 and 2001.
RESULTS: : Utilization. The number of concurrent medications increased over assessment times. Changes in children's pharmacotherapy occurred most frequently during hospitalization and from discharge to 3 months after discharge. Treatment with antipsychotics and mood stabilizers increased over assessment times, whereas selective serotonin reuptake inhibitor (SSRI) treatment decreased. Outcomes. Children treated with stimulants and risperidone 3 months after discharge had significantly improved behavioral ratings, adjusted for admission scores and concurrent medications. Children treated with SSRIs at 6 months after discharge had higher problem severity ratings. Those who maintained lithium and SSRI treatment between 6 and 12 months showed improvements.
CONCLUSIONS: : The complexity of pharmacotherapy for child inpatients ratchets upwards from admission through 1 year after discharge. Hospital-initiated treatment is commonly altered soon after discharge. Within the limitations of observational methodology, the postdischarge outcomes seem related to specific pharmacotherapy regimens.

Entities:  

Mesh:

Year:  2006        PMID: 16855463      PMCID: PMC2956076          DOI: 10.1097/01.jcp.0000227356.31203.8a

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  26 in total

1.  The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.

Authors:  Christina M Dording; David Mischoulon; Timothy J Petersen; Rebecca Kornbluh; Johanna Gordon; Andrew A Nierenberg; Jerrold E Rosenbaum; Maurizio Fava
Journal:  Ann Clin Psychiatry       Date:  2002-09       Impact factor: 1.567

2.  Psychotropic practice patterns for youth: a 10-year perspective.

Authors:  Julie Magno Zito; Daniel J Safer; Susan DosReis; James F Gardner; Laurence Magder; Karen Soeken; Myde Boles; Frances Lynch; Mark A Riddle
Journal:  Arch Pediatr Adolesc Med       Date:  2003-01

3.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

4.  Safeguards for children taking antidepressants strengthened.

Authors:  Carol Rados
Journal:  FDA Consum       Date:  2005 Jan-Feb

5.  Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.

Authors:  Daniel F Connor; Stephen J Glatt; Ivan D Lopez; Denise Jackson; Richard H Melloni
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-03       Impact factor: 8.829

6.  Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.

Authors:  Andrés Martin; Kathleen Koenig; George M Anderson; Lawrence Scahill
Journal:  J Autism Dev Disord       Date:  2003-02

7.  A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder.

Authors:  R P Malone; M A Delaney; J F Luebbert; J Cater; M Campbell
Journal:  Arch Gen Psychiatry       Date:  2000-07

8.  ADHD comorbidity findings from the MTA study: comparing comorbid subgroups.

Authors:  P S Jensen; S P Hinshaw; H C Kraemer; N Lenora; J H Newcorn; H B Abikoff; J S March; L E Arnold; D P Cantwell; C K Conners; G R Elliott; L L Greenhill; L Hechtman; B Hoza; W E Pelham; J B Severe; J M Swanson; K C Wells; T Wigal; B Vitiello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

9.  Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.

Authors:  Michael G Aman; Goedele De Smedt; Albert Derivan; Ben Lyons; Robert L Findling
Journal:  Am J Psychiatry       Date:  2002-08       Impact factor: 18.112

10.  Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care.

Authors:  Andrés Martin; Thomas Van Hoof; Dorothy Stubbe; Tierney Sherwin; Lawrence Scahill
Journal:  Psychiatr Serv       Date:  2003-01       Impact factor: 3.084

View more
  10 in total

Review 1.  Behavioral and pharmacogenetics of aggressive behavior.

Authors:  Aki Takahashi; Isabel M Quadros; Rosa M M de Almeida; Klaus A Miczek
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 2.  Brain serotonin receptors and transporters: initiation vs. termination of escalated aggression.

Authors:  Aki Takahashi; Isabel M Quadros; Rosa M M de Almeida; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2010-09-03       Impact factor: 4.530

3.  Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996-2004.

Authors:  Joseph C Blader; Gabrielle A Carlson
Journal:  Biol Psychiatry       Date:  2007-02-16       Impact factor: 13.382

4.  Long-term citalopram maintenance in mice: selective reduction of alcohol-heightened aggression.

Authors:  Elizabeth E Caldwell; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2007-10-20       Impact factor: 4.530

5.  Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.

Authors:  Joseph C Blader; Nina R Schooler; Peter S Jensen; Steven R Pliszka; Vivian Kafantaris
Journal:  Am J Psychiatry       Date:  2009-11-02       Impact factor: 18.112

Review 6.  The role of the serotonergic system at the interface of aggression and suicide.

Authors:  M Bortolato; N Pivac; D Muck Seler; M Nikolac Perkovic; M Pessia; G Di Giovanni
Journal:  Neuroscience       Date:  2013-01-16       Impact factor: 3.590

7.  Factors contributing to reduced caregiver strain in a publicly-funded child mental health system.

Authors:  Erin C Accurso; Ann F Garland; Rachel Haine-Schlagel; Lauren Brookman-Frazee; Mary J Baker-Ericzén
Journal:  J Emot Behav Disord       Date:  2015-09-01

8.  The neurobiological bases for development of pharmacological treatments of aggressive disorders.

Authors:  Allan Siegel; Suresh Bhatt; Rekha Bhatt; Steven S Zalcman
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

9.  Post-discharge services and psychiatric rehospitalization among children and youth.

Authors:  Sigrid James; Sherma J Charlemagne; Amanda B Gilman; Qais Alemi; Rhoda L Smith; Priya R Tharayil; Kimberly Freeman
Journal:  Adm Policy Ment Health       Date:  2010-09

10.  Frequency, characteristics and management of adolescent inpatient aggression.

Authors:  Immaculada Baeza; Christoph U Correll; Ema Saito; Dinara Amanbekova; Meena Ramani; Sandeep Kapoor; Raja Chekuri; Marc De Hert; Maren Carbon
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05-06       Impact factor: 2.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.